Therapeutic RSV protein F-antibody from the original Synagis® commercial drug targeting the RSV protein F-antigen, also referred to as Synagis® or palivizumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.
What our clients say
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
“Evidentic gives rapid access to originator biologics and different batches. For biosimilar developers and regulators, it will shorten the time to gauge the analytical acceptance range for multiple CQAs of biotherapeutics.”
|API type||Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
|Pharmacotherapeutic group||Immune sera immunoglobulins, specific immunoglobulins
|Target of antibody||RSV protein F
(Mechanism of action; Source EMA document)
|Palivizumab is a humanised IgG1κ monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
Palivizumab serum concentrations of approximately 30 μg/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model.
|Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)|
|Original license holder|
|Marketing authorisation numbers||EU/1/99/117/001 - 004
|Marketing authorisation holder||AbbVie Ltd
|Name of the manufacturer of the biological active substance||Boehringer Ingelheim Pharma GmbH & Co. KG
D-88397 Biberach an der Riss
660 MedImmune Court / 633 Research Court, Frederick, Maryland,
|Name and address of the manufacturer(s) responsible for batch release||AbbVie S .r.l. 04011 Campoverde di Aprilia(Latina)
|Max shelf life||48 months
|Storage conditions||2°C – 8°C
|List of excipients||Powder:
Water for injections